GLP-1 receptor agonists like semaglutide work by slowing gastric emptying and signaling satiety to your brainbut only if taken consistently at the right intervals
Recent hypotheses suggest that GIP induces appetite suppression through independent receptors in the brain, mitigates gastrointestinal side effects of GLP-1 action, and prevents desensitization of GLP-1 receptors, thereby acting as a biased GLP-1RA [87]
As evidence grows on the drugs effectiveness for a broader range of conditions, employers may face increased pressure to cover them, but these drugs impact on costs and premiums will remain a concern at the current prices and utilization levels
The case In May, Novo Nordisk moved the Delhi HC against DRL, seeking that the Indian firm and its distributors be restrained from using, manufacturing, selling, distributing, advertising, exporting semaglutide active pharmaceutical ingredient (API) or any product derived from it